Inactive Instrument

Intervacc AB Stock Nasdaq Stockholm

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

31/07	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
30/07	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT

Analysts' recommendations: Intervacc AB

20/05/24	Penser reiterates motivated value for Intervacc - report met expectations	FW
21/02/24	Penser lowers Intervacc's motivated value	FW
17/11/23	Penser makes minor estimate adjustments in Intervacc	FW
04/05/23	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
20/02/23	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Managers and Directors: Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	05/02/2026
Jan Persson DFI	Director of Finance/CFO	-	06/02/2020
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	11/06/2020

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	13/05/2026
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	01/01/2024
Björn Ingemar Odlander BRD	Director/Board Member	68	01/01/2025

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

20/08 Earnings release - Q2 2026

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	417M 43.6M 37.89M 35.38M 32.48M 61.24M 4.16B 62.31M 163M 2.07B 164M 160M 6.84B	P/E 2026 *	-5.56x	P/E 2027 *	-5.56x
Enterprise Value	324M 33.88M 29.44M 27.49M 25.23M 47.58M 3.23B 48.41M 127M 1.61B 127M 124M 5.31B	EV / Sales 2026 *	18.3x	EV / Sales 2027 *	11.8x
Free-Float	80.66%	Yield 2026 *	-	Yield 2027 *	-

31/07	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
30/07	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
29/07	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
29/07	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
22/05	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
15/05	Sweden's Intervacc Elects New Chair	MT
15/05	Appoints Emil Billbäck as chairman	RE
14/05	Intervacc elects Emil Billbäck as chairperson of board	RE
14/05	Intervacc AB Announces Board Changes	CI
13/05	Intervacc Q1 net sales down at SEK 3.4 million	RE
13/05	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
12/05	Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026	CI
16/04	Intervacc: Strangvac vaccine approved in Iceland	RE

30/07	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ
29/07	Intervacc: New Zealand order validates Strangvac’s position	AQ
29/07	Intervacc makes first export of Strangvac to New Zealand under Special Circumstances Permit	AQ
04/06	Redeye initiates coverage of Intervacc	AQ
22/05	Intervacc: Positive results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.05%	+2.80%	+38.17%	+74.12%	56.54B
ARGENX SE	-3.06%	-10.22%	+23.62%	+58.59%	53.6B
BIONTECH SE	+1.84%	+1.19%	-16.23%	-13.57%	22.91B
INSMED INCORPORATED	-0.15%	-5.99%	-11.49%	+344.51%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+0.15%	-0.77%	+23.76%	-11.52%	20.27B
GENMAB A/S	-0.67%	-1.73%	+33.09%	-31.09%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.45%	-7.24%	+17.67%	+563.14%	14.75B
PHARMAESSENTIA CORPORATION	+9.91%	+2.64%	+188.84%	+326.19%	13.53B
EXELIXIS, INC.	+3.83%	-1.38%	+49.52%	+165.13%	13.33B
Average	+1.15%	-1.88%	+38.55%	+163.94%	25.98B
Weighted average by Cap.	+0.13%	-1.70%	+31.41%	+121.97%

	2026 *	2027 *
Net sales	17.7M 1.85M 1.61M 1.5M 1.38M 2.6M 176M 2.64M 6.93M 87.94M 6.95M 6.8M 290M	30.05M 3.14M 2.73M 2.55M 2.34M 4.41M 299M 4.49M 11.77M 149M 11.8M 11.54M 492M
Net income	-80.8M -8.45M -7.34M -6.85M -6.29M -11.86M -805M -12.07M -31.65M -401M -31.72M -31.02M -1.32B	-83.65M -8.74M -7.6M -7.09M -6.51M -12.28M -833M -12.49M -32.76M -416M -32.84M -32.11M -1.37B
Net Debt	-93.05M -9.73M -8.45M -7.89M -7.24M -13.66M -927M -13.9M -36.44M -462M -36.53M -35.72M -1.52B	-63M -6.58M -5.72M -5.34M -4.9M -9.25M -628M -9.41M -24.67M -313M -24.73M -24.19M -1.03B

Intervacc AB Stock Nasdaq Stockholm

Stocks

Biotechnology & Medical Research

Valuation: Intervacc AB

Latest news : Intervacc AB

Analysts' recommendations: Intervacc AB

Press Releases: Intervacc AB

Managers and Directors: Intervacc AB

Bio Therapeutic Drugs

Financials

Company Profile